» Articles » PMID: 38746587

Efficacy of Behavioural Activation in the Treatment of Negative Symptoms in People with Schizophrenia Spectrum Disorders: A Systematic Review

Overview
Specialty Nursing
Date 2024 May 15
PMID 38746587
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Negative symptoms, frequently experienced by people with schizophrenia, can impair functional outcomes and quality of life. Negative symptoms typically affect motivation, communication, and the ability to live independently and are difficult to treat. Several meta-analyses suggest that cognitive behavioural therapy results in a modest reduction in negative symptoms. It is unclear if similar effects can be achieved using behavioural activation. Behavioural activation is a derivative of cognitive behavioural therapy that helps to improve social and emotional functioning by encouraging patients to engage in activities that they value whilst modifying the avoidance responses. Behavioural activation can be a standalone treatment for depressive symptoms that is equally as efficacious as cognitive behavioural therapy.

Objective: This systematic review aimed to identify and summarise the evidence about the efficacy of behavioural activation in treating negative symptoms.

Design: Systematic review.

Setting/participants: Two published studies conducted in South Korea and the United Kingdom recruited 55 patients.

Method: We searched five databases and four trial registries for clinical treatment trials of behavioural activation involving adults diagnosed with negative symptoms of schizophrenia. Studies were screened according to the inclusion criteria and assessed for quality.

Results: We identified 5023 published studies. After removing duplicates and conducting screening, two studies were included in this review. One study used a parallel non-randomised trial design whilst the other adopted a single group test-re-test design. Fifty-five participants were recruited from hospital and community settings. Both studies delivered 10 face-to-face sessions of behavioural activation; these were individual in one study and group sessions in the other. One study involved behavioural activation as the treatment whilst the other delivered behavioural activation with motivational interviewing. Neither study reported harms or adverse events.

Conclusions: Based on the included studies, there is low-quality evidence that behavioural activation may be helpful in the treatment of negative symptoms. Key limitations of the studies include small sample sizes and overall low study quality.

Study Registration: The protocol covering this review was registered with Open Science on 18 February 2022 (Registration DOI 10.17605/OSF.IO/57QSW; Weblink: https://osf.io/57qsw).

Tweetable Abstract: Behavioural activation holds promise in supporting patients experiencing negative symptoms of schizophrenia.

Citing Articles

Australian trial of behavioural activation for people with schizophrenia experiencing negative symptoms: a feasibility randomised controlled trial protocol.

Muyambi K, Walsh S, Dettwiller P, Tan K, Dennis S, Bressington D BMJ Open. 2024; 14(5):e080245.

PMID: 38719282 PMC: 11086511. DOI: 10.1136/bmjopen-2023-080245.


Impacts of a Self-directed Social Resources Study Program on Negative Symptoms and Quality of Life in Schizophrenia Outpatients: A Randomized Controlled Trial.

Nishimura Y, Yotsumoto K, Hashimoto T Kobe J Med Sci. 2024; 70(1):E15-E21.

PMID: 38644296 PMC: 11086633. DOI: 10.24546/0100488377.

References
1.
Uphoff E, Pires M, Barbui C, Barua D, Churchill R, Cristofalo D . Behavioural activation therapy for depression in adults with non-communicable diseases. Cochrane Database Syst Rev. 2020; 8:CD013461. PMC: 8094508. DOI: 10.1002/14651858.CD013461.pub2. View

2.
Staring A, Ter Huurne M, van der Gaag M . Cognitive Behavioral Therapy for negative symptoms (CBT-n) in psychotic disorders: a pilot study. J Behav Ther Exp Psychiatry. 2013; 44(3):300-6. DOI: 10.1016/j.jbtep.2013.01.004. View

3.
Bortolon C, Yazbek H, Norton J, Capdevielle D, Raffard S . The contribution of optimism and hallucinations to grandiose delusions in individuals with schizophrenia. Schizophr Res. 2019; 210:203-206. DOI: 10.1016/j.schres.2018.12.037. View

4.
Ekers D, Richards D, McMillan D, Bland J, Gilbody S . Behavioural activation delivered by the non-specialist: phase II randomised controlled trial. Br J Psychiatry. 2011; 198(1):66-72. DOI: 10.1192/bjp.bp.110.079111. View

5.
Sabe M, Zhao N, Crippa A, Kaiser S . Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. NPJ Schizophr. 2021; 7(1):43. PMC: 8438046. DOI: 10.1038/s41537-021-00171-2. View